Latest Payments News

Monadelphous Group Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.39 per share and setting the Dividend Reinvestment Plan price at AUD 21.49. The dividend relates to the six months ending June 2025, with payments scheduled for late September.

Domino’s Pizza Enterprises has updated its dividend announcement to include a DRP price of AUD 14.26 with a 1% discount, alongside an unfranked dividend of AUD 0.215 per share for the half-year ending June 2025.

Arena REIT has declared a quarterly distribution of 4.8125 cents per security, aligning with its FY26 guidance, while offering investors a discounted Dividend Reinvestment Plan option.

Arena REIT has announced its latest quarterly dividend of AUD 0.048125 per security, payable in November 2025, alongside a Dividend Reinvestment Plan offering a 1.5% discount for shareholders.

Iluka Resources has updated its dividend details for the first half of 2025, confirming a fully franked dividend of 2 cents per share and announcing a Dividend Reinvestment Plan price of AUD 6.0274.

EBR Systems has secured final CMS approval for Transitional Pass-Through reimbursement for its WiSE CRT System, effective October 1, 2025, enhancing hospital adoption prospects in the U.S.

SPDR S&P/ASX 200 ETF (STW) has announced an estimated ordinary dividend of AUD 0.836278 per security for the quarter ending 30 September 2025, with a Dividend Reinvestment Plan available to investors.

Bank of Queensland Limited announces a fully franked quarterly distribution of AUD 1.2182 per Capital Note 3 security, reflecting a 4.89% annualised yield tied to the 3-month BBSW plus margin.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Kalamazoo Resources has strategically expanded its Ashburton Gold Project in Western Australia by acquiring the contiguous Xanadu Gold Project and securing a new exploration licence, significantly increasing its exploration footprint amid a strong gold price environment.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

Orora Limited has confirmed its ordinary dividend for the six months ending June 2025 at 5 cents per share and announced the Dividend Reinvestment Plan price at AUD 2.0903, with payments scheduled for early October.